公开(公告)号：US20210024594A1

公开(公告)日：2021-01-28

申请号：US16967919

申请日：2019-02-07

Applicant: StemRIM Inc. ,  OSAKA UNIVERSITY

Inventor： Katsuto TAMAI ,  Takashi SHIMBO ,  Takehiko YAMAZAKI

IPC: C07K14/47 ,  A61P17/06

Abstract: The present inventors discovered that an HMGB1 fragment peptide having a specific amino acid sequence exhibits an effect of suppressing erythema, scaling (desquamation), and thickening (infiltration) of the skin in an animal model of psoriasis. Based on these findings, pharmaceutical compositions for the prevention and/or treatment of psoriasis, which comprise the HMGB1 fragment peptide having the specific amino acid sequence are provided.

公开(公告)号：US20200369736A1

公开(公告)日：2020-11-26

申请号：US16713202

申请日：2019-12-13

Applicant: STEMRIM INC. ,  OSAKA UNIVERSITY

Inventor： KATSUTO TAMAI ,  TAKEHIKO YAMAZAKI ,  TSUTOMU KANEZAKI ,  SHIGERU SAKURAI ,  YUKIKO NOGUCHI ,  MAYUMI ENDO ,  NATSUMI HAMABUCHI ,  KANA NAITO

IPC: C07K14/47

Abstract: (Objective) An objective of the present invention is to provide therapeutic agents that, in association with stimulation of PDGFRα-positive cells such as bone marrow mesenchymal stem cells, promote their mobilization into blood and accumulation in a damaged tissue, and induce tissue regeneration in a living body.(Means for solution) Multiple peptides were synthesized, and the migration-promoting activity of each peptide was evaluated. As a result, the present inventors successfully identified multiple peptides that have migration-promoting activity on a PDGFRα-positive bone marrow mesenchymal stem cell line (MSC-1). Further, the present inventors confirmed that the identified peptides also have migration-promoting activity on skin fibroblasts, which are PDGFRα-positive cells.